^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:Acute Myelogenous Leukemia
    Drug:Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Chronic Myeloid Leukemia)
    New
    Title:

    FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia

    Excerpt:
    On October 29, 2024, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2023
    Title:

    FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.

    Published date:
    05/11/2023
    Excerpt:
    The aim of the study was to pilot asciminib in combination with ATP competing tyrosine kinase inhibitors (TKI) asfirst-line therapies in CML pts to improve the rate of deep molecular response...Adult pts with newly diagnosed BCR::ABL1-positive CML were included in the study...The combination of asciminib as frontline therapy with ATP competing BCR::ABL1 inhibitors is associated with a high rate of deep molecular response...